| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
76,189 |
69,279 |
$8.75M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
74,903 |
66,509 |
$7.38M |
| 96361 |
Intravenous infusion, hydration; each additional hour |
5,820 |
5,174 |
$1.33M |
| 80053 |
Comprehensive metabolic panel |
45,457 |
40,333 |
$653K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
5,793 |
5,286 |
$571K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
14,373 |
12,581 |
$272K |
| 84484 |
|
9,697 |
7,064 |
$175K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,932 |
1,719 |
$121K |
| 70450 |
Computed tomography, head or brain; without contrast material |
597 |
536 |
$93K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
323 |
290 |
$59K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
798 |
666 |
$39K |
| 80320 |
|
339 |
276 |
$31K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
1,965 |
679 |
$28K |
| 95810 |
Polysomnography; sleep staging with 4 or more additional parameters |
43 |
35 |
$25K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
273 |
239 |
$24K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
174 |
160 |
$18K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
43,694 |
39,123 |
$10K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
139 |
123 |
$8K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
29 |
25 |
$7K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
1,040 |
823 |
$7K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
64 |
57 |
$7K |
| G0378 |
Hospital observation service, per hour |
181 |
99 |
$6K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
24 |
24 |
$5K |
| 17250 |
|
60 |
24 |
$4K |
| 71045 |
Radiologic examination, chest; single view |
21,015 |
18,730 |
$4K |
| 73130 |
|
33 |
27 |
$3K |
| 85027 |
|
68,958 |
60,770 |
$3K |
| 83690 |
|
17,829 |
15,954 |
$3K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
16 |
12 |
$3K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
12,590 |
11,129 |
$3K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
830 |
258 |
$2K |
| 97165 |
|
27 |
27 |
$2K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
18,534 |
16,201 |
$2K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
5,194 |
4,657 |
$858.56 |
| 85379 |
|
42 |
37 |
$729.88 |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
14 |
14 |
$635.88 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
1,754 |
1,616 |
$632.08 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
10,359 |
9,164 |
$549.46 |
| 83605 |
|
27 |
24 |
$517.73 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
3,703 |
3,106 |
$515.11 |
| J7050 |
Infusion, normal saline solution, 250 cc |
1,288 |
1,136 |
$337.03 |
| 82077 |
|
565 |
517 |
$311.63 |
| 97799 |
|
26 |
13 |
$281.14 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
13 |
13 |
$263.82 |
| 81001 |
|
7,663 |
6,872 |
$228.15 |
| J7999 |
Compounded drug, not otherwise classified |
93 |
75 |
$214.92 |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
334 |
300 |
$139.58 |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
262 |
253 |
$126.50 |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
478 |
117 |
$124.66 |
| 84703 |
|
11,941 |
10,672 |
$119.79 |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
406 |
95 |
$102.84 |
| 72125 |
Computed tomography, cervical spine; without contrast material |
13 |
12 |
$91.40 |
| 71046 |
Radiologic examination, chest; 2 views |
161 |
139 |
$63.18 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
4,384 |
3,926 |
$58.55 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
176 |
162 |
$6.08 |
| 81003 |
|
3,809 |
3,457 |
$4.94 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
2,428 |
2,164 |
$3.99 |
| J2060 |
Injection, lorazepam, 2 mg |
116 |
107 |
$0.63 |
| 81025 |
|
87 |
80 |
$0.00 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,995 |
1,468 |
$0.00 |
| 73610 |
|
14 |
12 |
$0.00 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
148 |
131 |
$0.00 |
| 82075 |
|
180 |
152 |
$0.00 |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
68 |
65 |
$0.00 |
| 97161 |
|
15 |
13 |
$0.00 |
| 87420 |
|
38 |
30 |
$0.00 |
| 84100 |
|
15 |
12 |
$0.00 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
16 |
13 |
$0.00 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
42 |
38 |
$0.00 |
| 87081 |
|
135 |
127 |
$0.00 |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
330 |
295 |
$0.00 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
559 |
505 |
$0.00 |
| 36415 |
Collection of venous blood by venipuncture |
87 |
74 |
$0.00 |
| 87430 |
|
108 |
105 |
$0.00 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
15 |
12 |
$0.00 |
| 83735 |
|
17 |
13 |
$0.00 |
| J1790 |
Injection, droperidol, up to 5 mg |
28 |
24 |
$0.00 |
| J3360 |
Injection, diazepam, up to 5 mg |
28 |
13 |
$0.00 |
| 96376 |
|
15 |
13 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
39 |
25 |
$0.00 |
| 80047 |
|
29 |
27 |
$0.00 |